Neuropathic pain is a complication of nerve injury that results from metabolic, infectious, chemical, or traumatic causes. Currently, there are no treatments to prevent or cure this condition. The cost of conducting a clinical trial for new treatments of neuropathic pain is high and over the last decade, most of these trials searching for analgesics with novel mechanism of action have failed. The Seeker desires to identify novel, minimally invasive biomarkers to predict therapeutic efficacy of analgesic treatments in patients with neuropathic pain.
This Challenge requires only a written proposal.
Neuropathic pain (NP) is an area of huge medical need, requiring novel and more efficacious treatment options for patients. It is thought that early identification of chronic pain leads to more successfully management outcomes. As NP can occur in many different etiologies, translation of pre-clinical animal models for NP (e.g. models of peripheral neuropathy) based on behavioral endpoints into robust clinical efficacy has proven difficult. The Seeker desires to identify novel biomarkers to track the neuropathophysiology and nerve function of patients with NP conditions to better predict and assess their response to analgesic therapies.
ABOUT THE SEEKER
AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on September 27, 2014. Late submissions will not be considered.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions.
What is a Theoretical-Licensing Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.